Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients
Ellen J. Collarini(University College London), Lawrence M. Kauvar, Stote L. Ellsworth(Trellis Bioscience (United States)), Stephen F. Carroll(IGM Biosciences (United States)), Gizette Sperinde, Ralph A. Tripp(University of Georgia), F. Eun-Hyung Lee(University of Rochester Medicine), Bruce A. Keyt, Orit Foord(Trellis Bioscience (United States)), William Harriman(Trellis Bioscience (United States)), Edward E. Walsh(University of Rochester), Larry J. Anderson(Children's Healthcare of Atlanta), Hai Wu(Trellis Bioscience (United States)), Minha Park(Trellis Bioscience (United States))
Cited by 96
Related Papers
Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders
|New England Journal of Medicine|1994|3.8k
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
|New England Journal of Medicine|2020|2.7k
Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome
|Science|2003|2.6k
Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults
|New England Journal of Medicine|2005|2.2k
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
|Nature|2020|1.6k